La vendita allo scoperto per Twist Bioscience dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Twist Bioscience. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Twist Bioscience (NASDAQ:TWST) Azioni, Report sulle vendite allo scoperto

TWIST BIOSCIENCE CORP

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

News

KVC Behavioral Healthcare Kentucky And Valvoline Partner To Expand Suicide Prevention Efforts Across The Commonwealth Of Kentucky

Rockwell Automation Launches EtherNet/IP In-cabinet Solution to Help Manufacturers Build Smarter, More Efficient Panels

Jefferies analyst Omar Nokta maintains Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) with a Buy and maintains $5 price target.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Safe Bulkers, Maintains $5 Price Target

PLUG

Plug Power Says GenEco Electrolyzers Go Live At The Green Box In Netherlands Showcasing Real-World Performance For European Customers

ProPetro Holding Corp. ("ProPetro" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) is pleased to announce that its PROPWR℠ division has secured its inaugural contract under which it will commit 80 megawatts of power generation capacity. This 10-year agreement represents a significant milestone for PROPWR, marking its first customer commitment and aligning with the Company's mission to "Rethink The Grid."
Executed in collaboration with a Permian-focused E&amp;P operator, the project involves PROPWR committing capacity of 80 megawatts, with asset deployment scheduled to begin in the third quarter of this year and continuing through 2026. PROPWR will deliver turnkey power to a distributed microgrid installation, utilizing in-field gas where utility power is unavailable to support production operations. This solution combines natural gas reciprocating engines and gas turbine generation to provide reliable power services under the contract. The comprehensive scope of service includes assets, onsite operations, maintenance, monitoring, an availability guarantee, and take-or-pay obligations for the customer supporting PROPWR's capacity commitment. This agreement not only underscores PROPWR's commitment to innovation and growth but also lays the groundwork for future expansion, with customer options to substantially increase PROPWR's committed capacity over time.
The Company is actively pursuing additional opportunities, and is engaged in negotiations for additional contracts that extend beyond today's announcement. As highlighted during the Company's first-quarter earnings call, PROPWR has already agreed to terms with one additional customer through a letter of intent and is working to finalize the associated contract. The Company anticipates sharing more exciting contract announcements in the near future.

PUMP

ProPetro Holding's PROPWR Division Secures 10-Yr Contract For 80 Megawatts Of Power Generation Capacity

ASPI

ASP Isotopes Enters Agreement Relating To Potential Acquisition Of Renergen Limited, With Goal Of Combined Group Expected To Be Accretive To 2026 Adj. EPS And Generate Over $300M EBITDA In 2030; Says Transaction 'has received irrevocable support from over 35% of Renergen shareholders and is expected to close during the third quarter of 2025 ahead of the planned QLE spin out.'

Mirion Technologies Announces Proposed $300M Private Offering Of Convertible Senior Notes Due 2030 With Option For Additional $45M

Telsey Advisory Group analyst Dana Telsey maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $43 price target.

BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $43 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $30 price target.

Reiteration

NTLA

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and maintains $1.5 price target.

D. Boral Capital Maintains Buy on PEDEVCO, Maintains $1.5 Price Target

QBTS

D-Wave Launches Commercial-Grade Advantage2 Quantum System To Tackle Complex Problems In Optimization, AI And Materials Simulation

Biotech

General

TRVI

Trevi Therapeutics Presents Additional Analyses From Phase 2a RIVER Trial At American Thoracic Society 2025 International Conference

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 -
- Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting eligibility for Priority Review; the BTD request was based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response -
- Biologics License Application (BLA) submission for veligrotug is on track for second half 2025 -
- Actively preparing organization for planned U.S. commercial launch in 2026 -
Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug ("veli"), an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye.
The THRIVE phase 3 clinical trial in active TED evaluated 5 infusions of veli or placebo every three weeks with primary topline analysis at week 15 and then followed patients through week 52.

VRDN

Viridian Therapeutics Announces Positive Long-Term Durability Data From THRIVE Phase 3 Clinical Trial Of Veligrotug In TED Patients

Toolstation Selects GXO As Logistics Partner In The Netherlands

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and lowers the price target from $8 to $3.

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $3

-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis –
-- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases –
-- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway –
-- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD --
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jpUKFDUv9SBOaAYEuDBVLMrIuE8vmhtiOpWfbossUQvn_ZgVR_ZhWKlfdYagPXw3J_EzkmVJYc5JjZ7ZCkYRpRxCeF1prBNvXpoYxY6gplo=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease (IBD).
This study was conducted at the Francis Crick Institute in London, U.K. by Dr. James Lee, a gastroenterologist and Clinician Scientist Group Leader at the Genetic Mechanisms of Disease Laboratory. Dr. Lee was the lead author of a landmark 2024 Nature paper that identified ETS2 as a master regulator of inflammatory responses in IBD, and uncovered a novel genetic mechanism behind the disease, which pointed to a new, potentially effective treatment strategy through MEK inhibition.
In this new study RNA sequencing was used to measure gene expression, with PAS-004 consistently outperforming the FDA-approved MEK inhibitor selumetinib across all tested doses (0.01 μM, 0.1 μM, and 1 μM), showing greater downregulation of ETS2 target genes, as well as experimentally validated MEK1/2 pathway genes. These data suggest more robust and durable MEK inhibition by PAS-004 under inflammatory conditions.

KTTA

Pasithea Therapeutics' New Preclinical Data Shows PAS-004 Provides Superior Inhibition Of ETS2-Driven Inflammatory Responses Compared To Selumetinib In Human Macrophage Model Of Chronic Inflammation In IBD

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) affirms FY2025 sales outlook from $2.00 million-$5.00 million to $2.00 million-$5.00 million.

Guidance

ARBE

Arbe Robotics Affirms FY2025 Sales Guidance of $2.00M-$5.00M

Autozi Regains Nasdaq Compliance As Share Price Meets $1.00 Minimum Bid Requirement Over 14 Consecutive Trading Days

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) reported quarterly losses of $(0.09) per share. This is a 35.71 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $40.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 60.00 percent. This is a 70.80 percent decrease over sales of $137.00 thousand the same period last year.

Earnings

Earnings Misses

Arbe Robotics Q1 Adj. EPS $(0.09) Up From $(0.14) YoY, Sales $40.00K Miss $100.00K Estimate

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) sees Q2 sales of $7.000 million-$7.100 million vs $7.17 million analyst estimate.

CRGO

Freightos Sees Q2 Sales $7.000M-$7.100M vs $7.17M Est

Press Releases

Twist Bioscience to Present at Upcoming Investor Conferences

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

Twist Bioscience Spins Out DNA Data Storage as Independent Company

Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

Comments

Twist Bioscience

Vendite allo scoperto

Twist Bioscience (NASDAQ:TWST) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO